XRP Holds Above $1 as CLARITY Act Stalls in Senate
XRP remains around the $1 mark as the CLARITY Act stalls in the Senate, raising questions about regulatory clarity an...
A clear look at the stablecoins that outperformed peers this year, with insights into drivers and risk considerations for future allocations.
26,211 articlesXRP remains around the $1 mark as the CLARITY Act stalls in the Senate, raising questions about regulatory clarity an...
IBM’s dramatic one-day plunge coincided with blockbuster bank profits, fueling a debate over whether markets are misp...
Bitcoin sits in the mid-60,000s after retreating from late-2025 highs, while on-chain activity slows and whale accumu...
As biotech manufacturing accelerates, repligen (rgen) 2025 earnings will shape how investors price the stock. This gu...
Berkshire Hathaway reduced its cash hoard to $373.3 billion by year-end 2025, a 2.1% drop from September, as Greg Abe...
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Investors are tracing a familiar 1990 Gulf War playbook as oil climbs and energy shares outperform, while the broader...
Ulta Beauty beat earnings and revenue expectations in the latest quarter, but investors focused on margin pressure an...
A sizable $12 million stake in a floor-and-decor retailer arrives as the stock trades off. This article breaks down t...
Federal Reserve Governor Christopher Waller signaled that he does not support additional rate hikes for now and expec...
Ford’s global footprint is narrowing as European and Chinese demand falters, leaving the US as the main growth engine...
Morgan Stanley halves Lucid's price target to $5, keeping an Underweight rating as production stoppages and a leaders...